Navigation Links
ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy
Date:2/28/2011

0 mg, 8.8% with ARCALYST 80 mg, and 7.6% with placebo), lower respiratory tract infection (0% with ARCALYST 160 mg, 5.0% with ARCALYST 80 mg, and 2.5% with placebo), musculoskeletal pain/discomfort (6.2% with ARCALYST 160 mg, 7.5% with ARCALYST 80 mg, and 8.9% with placebo), and headache, (3.7% with ARCALYST 160 mg, 6.3% with ARCALYST 80 mg, and 1.3% with placebo).

About the RE-SURGE StudyThe global RE-SURGE (REview of Safety Using Rilonacept in preventing Gout Exacerbations) study, was a double-blind, placebo-controlled study primarily focused on evaluation of safety. The trial was conducted in the United States, South Africa, Germany, and parts of Asia.  A total of 1,315 patients who were at risk for gout flares because they were initiating or taking uric acid-lowering drug treatment were randomly assigned in a 1:3 ratio to receive either weekly placebo injections (n=330) for 16 weeks or weekly subcutaneous injections of ARCALYST dosed at 320 mg as an initial loading dose and 160 mg thereafter (n=985) for a total of 16 weeks.  In this trial, a gout flare was defined as patient-reported acute articular pain typical of a gout attack that was deemed (by the patient and/or the investigator) to require treatment with an anti-inflammatory therapeutic.

Overall, the cumulative rate of infections was 20.1% in patients treated with ARCALYST and 19.1% in placebo patients.  Serious infections were reported in 0.5% of patients treated with ARCALYST® (rilonacept) and 0.9% of placebo patients.  Deaths were reported for 0.3% of patients treated with ARCALYST and 0.9% of placebo patients.

Specific adverse events that occurred at a frequency of at least 5% in any study group were: injection site reaction (15.2% with ARCALYST and 3.3 % with placebo), musculoskeletal pain/ discomfort (11.2% with ARCALYST and 9.7% with placebo), headaches (9.5% with ARCALYST and 8.8% with placebo), joint
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Mindray Medical Meets 2010 Product Development Targets and Announces Strong 2011 Pipeline
2. New IonWorks Barracuda Automated Patch Clamp System Meets Need for Affordable, Accelerated Screening of Ligand- & Voltage-Gated Ion Channels Via Direct Electrophysiology Assays
3. US Oncology Meets With Leading Pharmaceutical and Biotech Companies to Design Clinical Trials for the Cancer Fighting Drugs of Tomorrow
4. LEO Pharmas PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Condition
5. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
6. Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary Endpoint in a Study of Adult Subjects With a History of Grass Pollen Allergies
7. Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
8. Intercept Pharmaceuticals FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
9. Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints
10. MADIT-CRT Trial Meets Primary Endpoint
11. VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... CASTLE ROCK, Colo. , Aug. 28, 2014 /PRNewswire/ ... diagnostic company focused on obtaining FDA clearance for ... a rapid blood test for aiding in identifying children, ... who are at low risk for appendicitis, today announced ... Rodman & Renshaw 16 th Annual Global Investment ...
(Date:8/28/2014)... DIEGO , Aug. 28, 2014 Telik, ... development company that merged with MabVax Therapeutics, Inc. ... made significant progress related to the development of ... antibody was recovered using the Company,s internally developed ... the potential for multiple antibody based therapeutic and ...
(Date:8/28/2014)... DUBLIN, Ohio , Aug. 28, 2014 /PRNewswire/ ... rising competition in generics are adding pressure to ... internal resources. Company resources continue to shrink and ... complex. This has led companies to look for ... to commercialization and for keeping approved products on ...
Breaking Medicine Technology:Venaxis to Present at September Investor Conferences 2Venaxis to Present at September Investor Conferences 3Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 2Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 3Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 44 Key Factors to Consider When Choosing an Effective Regulatory Outsourcing Partner 24 Key Factors to Consider When Choosing an Effective Regulatory Outsourcing Partner 34 Key Factors to Consider When Choosing an Effective Regulatory Outsourcing Partner 4
(Date:8/29/2014)... VA (PRWEB) August 29, 2014 ... release of Clinical Trials Magnifier Weekly. , Clinical Trial ... the world every week and reports all the fresh ... FDAnews is able to extract just the information readers ... and drill down using links in the newsletter to ...
(Date:8/29/2014)... 2014 And the results are in! ... Caicos Islands, is voted a favorite with tourists and travelers ... the World in the Travelers' Choice Awards on the popular ... all across the globe pick their favorites, and the Turks ... multiple categories. , The Venetian on Grace Bay ...
(Date:8/29/2014)... CA (PRWEB) August 29, 2014 Recent ... have suggested that Americans today are working longer hours ... overworked and overstressed. APEC Water believes that drinking lots ... a Labor Day Sale on their most popular and ... and healthy. From now until 9/2/2014, customers can save ...
(Date:8/29/2014)... Farms, MI (PRWEB) August 29, 2014 ... structured data (relational tables) or unstructured data (document stores). ... while NoSQL products have basically managed the wide assortment ... only way to work with Big Data is with ... to solve the various aspects of all Big Data ...
(Date:8/29/2014)... Two Kelowna dentists are putting out ... a container filled with classroom materials, clinic supplies and even ... , “I don’t think words can describe ... Matson-Visscher. She and her husband, Dr. Jonathan Visscher, both partners ... part of New Reality International’s (NRI) mission to build and ...
Breaking Medicine News(10 mins):Health News:FDAnews Accounces New Newsletter: Clinical Trial Magnifier Weekly Provides the Most Up-to-Date Clinical Trial Data 2Health News:FDAnews Accounces New Newsletter: Clinical Trial Magnifier Weekly Provides the Most Up-to-Date Clinical Trial Data 3Health News:FDAnews Accounces New Newsletter: Clinical Trial Magnifier Weekly Provides the Most Up-to-Date Clinical Trial Data 4Health News:Relax this Labor Day Weekend with Great Savings on Easy-Install, Do-It-Yourself Drinking and Whole House Water Filters 2Health News:Scientel Announces Support for SQL Queries and Relational Tables Within Its Gensonix® NoSQL DB 2Health News:Scientel Announces Support for SQL Queries and Relational Tables Within Its Gensonix® NoSQL DB 3Health News:Scientel Announces Support for SQL Queries and Relational Tables Within Its Gensonix® NoSQL DB 4Health News:From Canada to Haiti: Kelowna Dentists Raise Funds to Ship Supplies to Self-Sustaining Village for Orphans 2Health News:From Canada to Haiti: Kelowna Dentists Raise Funds to Ship Supplies to Self-Sustaining Village for Orphans 3
... HealthDay Reporter , TUESDAY, July 19 (HealthDay News) -- ... cancer are undergoing chemotherapy may help prevent early menopause and ... July 20 issue of the Journal of the American ... hormone triptorelin when a patient is undergoing chemotherapy helped prevent ...
... , TUESDAY, July 19 (HealthDay News) -- The antidepressants ... provide no appreciable relief, and may raise the ... "The two classes of antidepressants most likely ... no more effective than placebo," the study authors said. ...
... July, 2011 The Research4Life partners today announced two ... case study competition on how HINARI, AGORA, and/or OARE ... a pediatrician from Nepal and Mr. Mulugeta Bayisa, a ... over 60 entries to the competition held in celebration ...
... Radiation Oncology (ASTRO) has named its 2011 class of ... designation at a ceremony during the Society,s 53rd Annual ... Beach Convention Center in Miami Beach, Fla. , "ASTRO ... members of the radiation oncology community and receiving this ...
... a part of its new initiative, Expanding Access to Opioid ... Europe and Central Asia (EECA), the International AIDS Society (IAS) ... in partnership with the Ukrainian Institute on Public Health Policy ... 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS ...
... HILL, N.C. Women who have breastfeeding difficulties in ... likely to suffer postpartum depression two months later compared ... women with breastfeeding difficulties should be screened for depressive ... the University of North Carolina at Chapel Hill. ...
Cached Medicine News:Health News:Drug May Prevent Chemo-Linked Menopause in Breast Cancer Patients 2Health News:Drug May Prevent Chemo-Linked Menopause in Breast Cancer Patients 3Health News:Two Antidepressants Given to Dementia Patients Ineffective: Study 2Health News:Joint winners announced in Research4life global case study competition 2Health News:Joint winners announced in Research4life global case study competition 3Health News:ASTRO announces 2011 Fellows class 2Health News:International AIDS Society to launch Virtual Media Centre in July to support opioid substitution therapy in Eastern Europe and Central Asia 2Health News:International AIDS Society to launch Virtual Media Centre in July to support opioid substitution therapy in Eastern Europe and Central Asia 3Health News:International AIDS Society to launch Virtual Media Centre in July to support opioid substitution therapy in Eastern Europe and Central Asia 4Health News:Mothers with breastfeeding difficulties more likely to suffer postpartum depression 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: